525 related articles for article (PubMed ID: 32437068)
1. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
[TBL] [Abstract][Full Text] [Related]
2.
Mitobe Y; Ikeda K; Suzuki T; Takagi K; Kawabata H; Horie-Inoue K; Inoue S
Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31501276
[TBL] [Abstract][Full Text] [Related]
3. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO.
Qin Z; Zheng X; Fang Y
Biochem Biophys Res Commun; 2019 Aug; 516(2):486-493. PubMed ID: 31230752
[TBL] [Abstract][Full Text] [Related]
5. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
Han C; Fu Y; Zeng N; Yin J; Li Q
Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p.
Mu X; Wu H; Liu J; Hu X; Wu H; Chen L; Liu W; Luo S; Zhao Y
Biomed Pharmacother; 2020 May; 125():109989. PubMed ID: 32062549
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
Huang W; Su X; Yan W; Kong Z; Wang D; Huang Y; Zhai Q; Zhang X; Wu H; Li Y; Li T; Wan X
Prostate; 2018 Dec; 78(16):1248-1261. PubMed ID: 30105831
[TBL] [Abstract][Full Text] [Related]
8. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.
Zhang X; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
Sci Rep; 2020 May; 10(1):7662. PubMed ID: 32376943
[TBL] [Abstract][Full Text] [Related]
9. LncRNA TMPO-AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer.
Zhao H; Ding F; Zheng G
FASEB J; 2020 Sep; 34(9):11382-11394. PubMed ID: 32692467
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers.
Zheng Q; Jia J; Zhou Z; Chu Q; Lian W; Chen Z
DNA Cell Biol; 2021 Jul; 40(7):848-857. PubMed ID: 34096793
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients.
Mohammadrezakhani H; Baradaran B; Shanehbandi D; Asadi M; Hashemzadeh S; Hajiasgharzadeh K; Safaralizadeh R
J Gastrointest Cancer; 2020 Sep; 51(3):952-956. PubMed ID: 31768869
[TBL] [Abstract][Full Text] [Related]
13. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.
Wu J; Xu W; Ma L; Sheng J; Ye M; Chen H; Zhang Y; Wang B; Liao M; Meng T; Zhou Y; Chen H
Aging (Albany NY); 2021 Jul; 13(14):18191-18222. PubMed ID: 34289449
[TBL] [Abstract][Full Text] [Related]
14. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
[TBL] [Abstract][Full Text] [Related]
15. A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability.
Jadaliha M; Gholamalamdari O; Tang W; Zhang Y; Petracovici A; Hao Q; Tariq A; Kim TG; Holton SE; Singh DK; Li XL; Freier SM; Ambs S; Bhargava R; Lal A; Prasanth SG; Ma J; Prasanth KV
PLoS Genet; 2018 Nov; 14(11):e1007802. PubMed ID: 30496290
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
17. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54.
Liu B; Yao P; Xiao F; Guo J; Wu L; Yang Y
J Transl Med; 2021 Aug; 19(1):333. PubMed ID: 34353336
[TBL] [Abstract][Full Text] [Related]
18. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
Luo N; Zhang K; Li X; Hu Y
J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
